Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects

Daewoong Pharmaceutical

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: DWC20155; Drug: DWC20156

Study type: Interventional

Funder types: Industry

Identifiers

NCT02704559

DW_DWJ1366001

Details and patient eligibility

About

A randomized, open-label, oral dose, crossover study to explore drug-drug interactions between DWC20155 and DWC20156 in healthy subjects.

Enrollment: 40 patients

Sex: All

Ages: 19 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Accepts healthy volunteers.

Exclusion criteria

• Who has allergy to investigational product

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

Study effect of DWC20156 on DWC20155 PK

Experimental group

Description:

To study effect of DWC20156 on DWC20155 PK

Treatment:

Drug: DWC20156

Study effect of DWC20155 on DWC20156 PK

Experimental group

Description:

To study effect of DWC20155 on DWC20156 PK

Treatment:

Drug: DWC20155